Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
Press Releases

Press Releases

All Releases
SUMAVEL DosePro is Granted First European Approval
Dec 07, 2010
Aradigm to Earn 3% Royalty on Net Sales HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that Zogenix, Inc. ("Zogenix", Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH ("Desitin") were granted approval of the Marketing Authorization Application
Aradigm Announces Third Quarter 2010 Financial Results
Nov 11, 2010
Company Eliminates $9.1M in Debt with Completion of Debt for Equity Transaction and Announces Awards of Over $733,000 in Government Grants HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced financial results for the third quarter and nine months
Aradigm Appoints Tamar Howson to Board of Directors
Nov 04, 2010
Well-Known Industry Expert Strengthens Business Development Focus HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced it appointed Tamar D. Howson to its board of directors. Ms. Howson brings significant business development and life sciences
Aradigm Awarded Three Therapeutic Discovery Tax Credit Grants Totaling Over $733,000 for Inhaled Liposomal Ciprofloxacin Program
Nov 02, 2010
HAYWARD, Calif., Nov 02, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that it received notification from the U.S. Internal Revenue Service (IRS) that it was approved to receive three grants in the amount of $244,479.25 each for qualified investments in
Aradigm Reports Successful Phase 2b Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin
Oct 20, 2010
Primary Endpoint - Reduction in Bacterial Load - Met
Positive Trends Observed in Time to First Exacerbation and Reduced Number of Exacerbations
Statistically Significant Reduction in the Need for Other Antibiotics

Aradigm to Present at the 9th Annual BIO Investor Forum on October 6
Oct 04, 2010
HAYWARD, Calif., Oct 04, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer Igor Gonda, Ph.D., will present at the 2010 Annual BIO Investor Forum on Wednesday, October 6, 2010, at 1:30 p.m. Pacific time.
Aradigm CEO Igor Gonda to Be Featured Guest Interview on StockGoodies.com Radio on September 30
Sep 30, 2010
HAYWARD, Calif., Sep 30, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB: ARDM) ("Aradigm") announced today that CEO Igor Gonda will be the featured guest interview on the fastest growing Stock Trading community, StockGoodies.com Radio. The interview will be held on September 30, 2010 at 8:00
Aradigm Announces Exercise of Warrants for Proceeds of Approximately $891,000
Sep 23, 2010
All Warrants Issued in June 2010 Private Placement Are Exercised
Aradigm Closes Equity for Debt Transaction with Novo Nordisk A/S
Sep 20, 2010
$9.1 Million in Debt Extinguished in Exchange for 26 Million Shares of Common Stock
Aradigm Presents Results Supporting Once-Daily Dosing With Its Inhaled Liposomal Ciprofloxacin Formulations at the 2010 European Respiratory Society (ERS) Annual Congress
Sep 17, 2010
HAYWARD, Calif., Sep 17, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) ("Aradigm") today announced it is presenting data on September 22, 2010, from its Phase 1 studies at the ERS Annual Congress in Barcelona, Spain. The podium presentation elaborates on the pharmacokinetic parameters of
Aradigm Announces Second Quarter 2010 Financial Results
Aug 12, 2010
Two Key Transactions Strengthen Balance Sheet - Company Raises $4.1M and Will Eliminate $9.1M in Debt
Aradigm Announces Equity for Debt Transaction with Novo Nordisk
Aug 02, 2010
$9.1 Million in Debt Extinguished in Exchange for 26 Million Shares of Common Stock
Aradigm Announces Private Placement for $5 Million
Jun 21, 2010
Proceeds Will Further Development of Inhaled Liposomal Ciprofloxacin for the Treatment of Severe Respiratory Diseases
Aradigm Presents at the 2010 International Conference of the American Thoracic Society
May 17, 2010
Unique Pharmacokinetic Profile and Good Tolerability was Demonstrated for ARD-3150
Aradigm Announces First Quarter 2010 Financial Results
May 13, 2010
Milestone Receipt and Expense Reduction Efforts Significantly Reduce Net Loss
Aradigm Receives FDA Clearance for Clinical Trial of Inhaled Liposomal Ciprofloxacin in Pediatric Patients With Cystic Fibrosis
May 05, 2010
HAYWARD, Calif., May 05, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application.
Aradigm Completes Enrollment and Doses Last Patient in Long Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
Mar 25, 2010
HAYWARD, Calif., Mar 25, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that the last patient was enrolled and received the first dose in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in
Aradigm Announces Fourth Quarter 2009 and Full Year Financial Results
Mar 23, 2010
Net Loss is Reduced by 39% While Advancing Bronchiectasis Clinical Program
Aradigm Doses First Patient in Its Second Phase 2b Clinical Trial of Inhaled Liposomal Ciprofloxacin in Bronchiectasis Patients
Feb 23, 2010
HAYWARD, Calif., Feb 23, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial, an international, randomized, double-blind,
Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale of SUMAVEL* DosePro*
Feb 04, 2010
HAYWARD, Calif., Feb 04, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") announced today that it received the $4 million milestone payment from Zogenix, Inc. ("Zogenix") based upon the first commercial sale in the U.S. of SUMAVEL* DosePro* (sumatriptan injection)
Displaying 121 - 140 of 236
CONTACT NEWS & EVENTS LEGAL SITE MAP ©2018 Aradigm Corporation. All Rights Reserved.